The consequences of risk reducing salpingo-oophorectomy: The case for a coordinated approach to long-term follow up post surgical menopause

Familial Cancer

Volumn 11, Issue 3, 2012, Pages 403-410

  Pezaro, Carmel ^a   James, Paul ^a,b   McKinley, Joanne ^a   Shanahan, Mary ^a   Young, Mary Anne ^a   Mitchell, Gillian ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

BRCA1 gene; BRCA2 gene; Comprehensive health care; Menopause; Osteoporosis; Salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER RISK; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOPOROSIS; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEXUAL DYSFUNCTION; SURGICAL APPROACH;

BRCA1 PROTEIN; BRCA2 PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MENOPAUSE; MIDDLE AGED; MUTATION; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PREMENOPAUSE; QUESTIONNAIRES; RISK REDUCTION BEHAVIOR; SALPINGOSTOMY;

EID: 84870459726     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-012-9527-5     Document Type: Article

References (33)

1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343(8899):692-695
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130
3. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R, Nogues C, Faivre L, Gesta P, van Leeuwen FE, Ausems MG, Osorio A, Caldes T, Simard J, Lubinski J, Gerdes AM, Olah E, Furhauser C, Olsson H, Arver B, Radice P, Easton DF, Goldgar DE (2009) Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the international BRCA1/2 carrier cohort study. Cancer Epidemiol Biomarkers Prev 18(2):601-610
4. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374(9698):1371-1382
5. McGuire V, Jesser CA, Whittemore AS (2002) Survival among U.S. women with invasive epithelial ovarian cancer. Gynecol Oncol 84(3):399-403
6. Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA (2007) No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer 96(9):1335-1342
7. Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dorum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2009) Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 46(9):593-597
8. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296(2):185-192
9. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, Evans DG, Lynch H, Eeles RA, Neuhausen SL, Daly MB, Matloff E, Blum JL, Sabbatini P, Barakat RR, Hudis C, Norton L, Offit K, Rebbeck TR (2008) Risk-reducing salpingooophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26(8):1331-1337
10. Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingooophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80-87
11. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967-975
12. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA (2008) International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122(9): 2017-2022
13. Skytte AB, Gerdes AM, Andersen MK, Sunde L, Brondum-Nielsen K, Waldstrom M, Kolvraa S, Cruger D (2010) Riskreducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 77(4): 342-349
14. Fry A, Busby-Earle C, Rush R, Cull A (2001) Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 10(3):231-241
15. Elit L, Esplen MJ, Butler K, Narod S (2001) Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 1(3-4):149-156
16. Tiller K, Meiser B, Gould L, Tucker K, Dudding T, Franklin J, Friedlander M, Andrews L (2005) Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer. Psychooncology 14(4):249-261
17. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23(28):6890-6898
18. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK (2006) The impact of hormone replacement therapy on menopausal symptoms in younger highrisk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24(22):3576-3582
19. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 112(3): 594-600
20. Hadjidakis D, Kokkinakis E, Sfakianakis M, Raptis SA (1999) The type and time of menopause as decisive factors for bone mass changes. Eur J Clin Invest 29(10):877-885
21. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ III (2007) Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69(11):1074-1083
22. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ III, Rocca WA (2009) Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 16(1):15-23
23. Domchek SM, Rebbeck TR (2007) Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 19(1):27-30
24. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10):821-828
25. Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, Rebbeck TR, Nathanson KL, Domchek SM (2011) Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingooophorectomy Familial Cancer. doi:10.1007/s10689- 011-9480-8
26. Schneider HP, Heinemann LA, Rosemeier HP, Potthoff P, Behre HM (2000) The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric 3:50-58
27. Heinemann LA, Potthoff P, Schneider HP (2003) International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes 1:28
28. Antill Y, Reynolds J, Young MA, Kirk J, Tucker K, Bogtstra T, Wong S, Dudding T, Di Iulio J, Phillips KA (2006) Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer. Eur J Cancer 42(5):621-628
29. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 23(31): 7804-7810
30. Kotz K, Alexander JL, Dennerstein L (2006) Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women. J Womens Health (Larchmt) 15(8):898-908
31. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V (2008) Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 19(10): 1669-1680
32. Chapman JS, Powell CB, McLennan J, Crawford B, Mak J, Stewart N, Chen LM (2011) Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol 122:339-343
33. Campfield Bonadies D, Moyer A, Matloff ET (2011) What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo- oophorectomy. Fam Cancer 10(1):79-85. doi: 10.1007/s10689-010-9384-z